Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome (AXSM) Q3 Earnings Top, Pre-Launch Activities Continue
11:28am, Tuesday, 09'th Nov 2021
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2021 Results - Earnings Call Transcript
01:34pm, Monday, 08'th Nov 2021
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2021 Results - Earnings Call Transcript
Why Axsome Therapeutics Stock Is Rising Today
12:37pm, Monday, 08'th Nov 2021
The company provided its third-quarter update.
Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021
07:00am, Wednesday, 20'th Oct 2021
Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time
What's Happening With Axsome Therapeutics Stock?
11:00am, Monday, 18'th Oct 2021
Last month we discussed that Axsome Therapeutics stock is likely to continue to see higher levels after it rose 6% in a week following the U.S. FDA's acceptance of a new drug application for the compa
Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million
07:00am, Monday, 18'th Oct 2021
$100 million now available upon the potential FDA approval of AXS-05
3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
06:21am, Sunday, 17'th Oct 2021
These stocks are expected to put up big gains in a short amount of time.
Why Axsome Therapeutics Stock Rocketed Higher This Week
10:00am, Friday, 15'th Oct 2021
Optimism among investors is growing for the possible approval of the biotech's MDD drug.
1 Beaten-Down Stock With 10X Potential
10:30am, Thursday, 14'th Oct 2021
This biotech is down, but it isn't out just yet.
Why Axsome Therapeutics Stock Caught Fire in September
10:45am, Wednesday, 06'th Oct 2021
This beaten-down biotech regained some lost ground last month.
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Axsome Therapeutics,
2 Best Biotech Stocks to Buy Right Now
07:00am, Saturday, 25'th Sep 2021
Aurinia Pharmaceuticals and Axsome Therapeutics are two names that growth investors should have on their radars right now.
Do Options Traders Know Something About Axsome (AXSM) Stock We Don't?
03:21pm, Friday, 24'th Sep 2021
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
Axsome Therapeutics: Amid The FDA Difficulty Is A Huge Opportunity
04:28am, Friday, 24'th Sep 2021
Among various companies being negatively impacted by a hypersensitive FDA environment, Axsome Therapeutics shares recently tumbled. Amid the aforesaid debacle, AXS-05 received a "stand by" notice from
Why Wall Street Thinks This Biotech Stock Can Triple Your Money
06:43am, Thursday, 23'rd Sep 2021
The risks are huge, but so are the potential returns.
